ShangPharma, a China-based pharmaceutical and biotechnology research and development outsourcing company, has appointed William Dai as chief financial officer (CFO). Kevin Penghui Chen, current CFO and chief operating officer (COO), will become president and continue his role as COO.
Dai has more than 17 years of experience in accounting, financial management, and the capital markets. Prior to ShangPharma, he served as CFO of China Nepstar Chain Drugstore in Shenzhen, China since January 2009. From 2006 to 2008, Dai was CFO and vice chair of the executive committee at MicroPort Medical in Shanghai, China. From 1993 to 2005, he held a variety of financial and senior managerial roles at multinational companies in China and the US.
Dai holds a MBA with an emphasis in finance from Michigan State University, and a bachelor’s degree in international business and English from Shanghai University’s College of International Business in Shanghai, China.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.